Prescription Arthritis Medications

Prescription Arthritis Medications Market Outlook

The global prescription arthritis medications market is projected to reach approximately USD 90 billion by 2035, growing at a compound annual growth rate (CAGR) of 7.5% from 2025 to 2035. This robust growth can be attributed to the increasing prevalence of arthritis conditions, rising geriatric populations, and advancements in medication formulations and delivery mechanisms. Moreover, the heightened awareness regarding the availability of effective treatments has spurred market growth. The continuous evolution in drug discovery and development, coupled with the growing investment in research and development by pharmaceutical companies, is also expected to fuel the market further. Lastly, supportive government initiatives aimed at enhancing healthcare accessibility and affordability are adding momentum to the growth trajectory of the market.

Growth Factor of the Market

Several factors are propelling the growth of the prescription arthritis medications market. The increasing incidence of arthritis, particularly among the aging population, necessitates consistent and effective treatment options to manage pain and inflammation. Additionally, ongoing research and development efforts are yielding novel therapies, providing healthcare professionals with more choices to tailor treatments based on individual patient needs. Technological advancements, such as the incorporation of biologics and targeted therapies, have revolutionized treatment protocols, improving patient outcomes significantly. The rising awareness regarding the importance of early diagnosis and treatment is leading to increased consultations and prescriptions. Furthermore, the trend toward personalized medicine is enabling more specific treatment plans based on genetic and phenotypic characteristics, thereby enhancing therapeutic efficacy.

Key Highlights of the Market

• Projected market growth of USD 90 billion by 2035.
• Increasing prevalence of arthritis among the aging population.
• Technological advancements in drug development.
• Growing awareness of treatment options driving prescriptions.
• Shift toward personalized medicine for improved patient outcomes.

By Product Type

NSAIDs:

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of arthritis due to their effectiveness in alleviating pain and reducing inflammation. These medications function by inhibiting the enzymes responsible for producing prostaglandins, which are compounds that promote inflammation and pain sensations. Commonly prescribed NSAIDs include ibuprofen and naproxen, which have been utilized extensively in clinical practice. The segment is expected to witness notable growth, as they are often the first line of treatment for arthritis patients due to their accessibility and affordability. Moreover, the entry of newer NSAIDs with improved safety profiles and efficacy may further drive market expansion within this product category.

Analgesics:

Analgesics represent another prominent segment within the arthritis medications market, primarily focusing on pain relief rather than addressing inflammation. These medications are crucial for patients experiencing chronic pain associated with arthritis conditions. Acetaminophen is one of the most commonly used analgesics, providing effective pain relief while posing fewer gastrointestinal risks compared to NSAIDs. The demand for analgesics is anticipated to grow as an increasing number of patients seek relief from ongoing discomfort. Additionally, the growing trend of self-medication among patients for mild to moderate pain is expected to boost the sales of over-the-counter analgesics.

DMARDs:

Disease-modifying antirheumatic drugs (DMARDs) are critical in managing autoimmune forms of arthritis, particularly rheumatoid arthritis. DMARDs work by suppressing the immune system's activity, thereby slowing disease progression and preventing joint damage. Methotrexate remains a cornerstone drug within this category, with its widespread use due to its effectiveness and established safety profile. As awareness regarding the importance of early treatment in preventing long-term joint damage increases, the demand for DMARDs is likely to rise significantly. Furthermore, the introduction of novel DMARDs with improved efficacy and fewer side effects is expected to expand treatment options for patients, thereby propelling market growth.

Corticosteroids:

Corticosteroids are potent anti-inflammatory medications that are typically used in the management of acute flare-ups of arthritis. They work by mimicking the effects of hormones produced by the adrenal glands, thereby reducing inflammation and suppressing the immune response. Prednisone is one of the most commonly utilized corticosteroids for treating arthritis. This segment is expected to experience steady demand as corticosteroids provide quick relief in severe cases and are often used in conjunction with other medications to enhance treatment efficacy. However, the long-term use of corticosteroids raises concerns over potential side effects, leading to a rising preference for alternative therapies. Nevertheless, their role remains indispensable in acute care settings.

Biologics:

Biologics are a revolutionary class of medications that target specific components of the immune system to reduce inflammation and halt disease progression, particularly in conditions like rheumatoid arthritis and psoriatic arthritis. Drugs like adalimumab, which is a monoclonal antibody, have shown significant effectiveness in managing these chronic conditions. The biologics segment has witnessed remarkable growth over the past decade, driven by their ability to provide significant improvements in quality of life for patients. As the market continues to evolve, further advancements in biologic therapies, including biosimilars, are expected to broaden treatment options and increase accessibility for patients. The high cost associated with biologics may be a limiting factor, but the long-term benefits they offer justify their usage for many patients.

By Application

Osteoarthritis:

Osteoarthritis is the most prevalent form of arthritis, characterized by the degeneration of cartilage and the underlying bone, leading to pain and stiffness. The treatment landscape for osteoarthritis includes a combination of lifestyle modifications, physical therapy, and pharmacological interventions. The demand for medications, particularly NSAIDs and analgesics, is high due to the chronic pain associated with this condition. As the population ages and the prevalence of obesity increases, which is a significant risk factor for osteoarthritis, the market for osteoarthritis treatments is expected to expand substantially. Furthermore, ongoing research into innovative therapies, such as regenerative medicine and biologics, may enhance treatment outcomes for osteoarthritis patients.

Rheumatoid Arthritis:

Rheumatoid arthritis is an autoimmune disorder that causes chronic inflammation of the joints, leading to significant morbidity and functional impairment. The management of rheumatoid arthritis typically involves DMARDs, NSAIDs, and corticosteroids, depending on the severity of the disease. The demand for biologics has soared as they offer targeted treatment options that can slow disease progression and prevent joint damage. As awareness increases regarding the importance of early intervention and effective disease management, the market for rheumatoid arthritis medications is predicted to continue its upward trajectory. Additionally, clinical advances in combination therapies that utilize both biologics and traditional DMARDs are expected to improve treatment responses.

Psoriatic Arthritis:

Psoriatic arthritis is a chronic inflammatory condition that affects not only the joints but also the skin, leading to significant discomfort and disability. The treatment of psoriatic arthritis often involves a combination of DMARDs, biologics, and NSAIDs to manage symptoms and prevent joint damage. The evolving understanding of the condition has led to the development of new treatment strategies that target specific inflammatory pathways, thus enhancing therapeutic efficacy. The growing recognition of the psychosocial impact of psoriatic arthritis on patients has also led to an increased focus on holistic treatment approaches, which is driving market growth. As more patients seek effective management options, the demand for medications tailored for psoriatic arthritis is expected to rise significantly.

Ankylosing Spondylitis:

Ankylosing spondylitis is a chronic inflammatory arthritis that primarily affects the spine, leading to painful stiffening and reduced mobility. Treatment options for ankylosing spondylitis typically include NSAIDs, DMARDs, and biologics, particularly TNF inhibitors. The growing recognition of ankylosing spondylitis as a significant cause of disability has led to increased emphasis on early diagnosis and treatment. The rising prevalence of the condition, particularly among younger adults, is likely to drive demand for effective medications. Additionally, advancements in biologic therapies and the introduction of novel agents are expected to improve patient outcomes and compliance, further boosting the market.

Others:

This category encompasses various other forms of arthritis and related conditions that may not fit neatly into the aforementioned classifications. Treatment approaches for these conditions can vary widely, often necessitating a tailored combination of medications to address the unique symptoms and disease progression. For instance, juvenile idiopathic arthritis and gout are among the conditions falling under this category. The market for medications targeting these other arthritis types is anticipated to grow as awareness of these diseases increases and as specialists develop more effective treatment regimens. Furthermore, the expanding portfolio of specialty drugs and advancements in personalized medicine are expected to enhance treatment options across this diverse segment.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a critical role in the distribution of prescription arthritis medications, particularly for patients requiring specialized care or those admitted for acute management of their conditions. These pharmacies are equipped to provide comprehensive medication management, ensuring that patients receive appropriate therapies tailored to their clinical needs. The demand for arthritis medications through hospital pharmacies is expected to remain strong due to the increasing number of hospital admissions related to arthritis exacerbations and related surgical procedures. Furthermore, hospital pharmacies often engage in collaborative care efforts with rheumatologists and other specialists, promoting optimal therapeutic outcomes for patients.

Retail Pharmacies:

Retail pharmacies serve as one of the most accessible sources for patients to obtain prescription arthritis medications. This distribution channel encompasses both chain and independent pharmacies, providing convenience to patients seeking over-the-counter and prescription medications. The growth of the retail pharmacy segment is driven by the increasing emphasis on patient-centered care and the convenience of obtaining medications without the need for hospital visits. Enhanced customer service, including medication counseling and adherence programs, contributes to the popularity of retail pharmacies among arthritis patients. Additionally, strategic partnerships between pharmaceutical companies and retail pharmacy chains are expected to bolster the availability of arthritis medications in this channel.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for prescription arthritis medications, particularly in the wake of the COVID-19 pandemic. The convenience of ordering medications from home, coupled with the ability to easily compare prices and access a wider range of products, has propelled the growth of this segment. E-commerce platforms dedicated to pharmaceuticals are increasingly offering home delivery services, enhancing accessibility for patients with mobility challenges. However, the online pharmacy sector is also subject to regulatory scrutiny, with emphasis on ensuring the authenticity of medications and patient safety. As more patients turn to online pharmacies for their prescription needs, robust regulatory frameworks will be crucial in maintaining trust and safety in this evolving distribution channel.

By Ingredient Type

Celecoxib:

Celecoxib is a selective COX-2 inhibitor primarily used for managing pain and inflammation associated with arthritis. As a member of the NSAID class, it provides the benefits of reduced gastrointestinal side effects commonly seen with traditional NSAIDs. The drug’s targeted action has made it a popular choice among healthcare professionals for treating osteoarthritis and rheumatoid arthritis. The increasing patient preference for medications with better safety profiles is anticipated to drive the growth of this ingredient in the market. Additionally, the introduction of generic versions of celecoxib is expected to enhance market accessibility and affordability.

Ibuprofen:

Ibuprofen is one of the most commonly used over-the-counter NSAIDs for pain relief in arthritis patients. Its wide availability and effectiveness in reducing inflammation make it a preferred choice for both acute and chronic pain management. With a long history of clinical use and a favorable safety profile, ibuprofen remains a staple in the treatment of various arthritis forms. The growing trend of self-medication, particularly for mild to moderate pain, is expected to sustain demand for ibuprofen. Furthermore, educational campaigns highlighting the importance of pain management will likely drive increased utilization of this ingredient among patients.

Methotrexate:

Methotrexate is a cornerstone DMARD used primarily in the management of rheumatoid arthritis. Its ability to suppress the immune system and slow disease progression makes it an essential treatment option for many patients. The effectiveness of methotrexate, coupled with its cost-effectiveness compared to newer biologics, continues to drive its usage in clinical practice. As the understanding of rheumatoid arthritis evolves, methotrexate remains a key part of combination therapy approaches, where it is often used alongside biologics for enhanced efficacy. Continuous research into optimizing dosing regimens and minimizing side effects will further solidify methotrexate’s role in the arthritis medication market.

Prednisone:

Prednisone is a corticosteroid that provides rapid relief from inflammation and pain associated with arthritis. It is particularly useful in managing acute flares, making it an essential tool in rheumatology. While effective, long-term use of prednisone poses risks of side effects, which may limit its use in chronic management of arthritis. However, its role in bridging therapy during transitions to other treatments remains significant. The demand for prednisone may experience fluctuations, influenced by the growing trend towards alternative treatment strategies; however, it will continue to play a role in acute care settings due to its efficacy in rapidly controlling symptoms.

Adalimumab:

Adalimumab is a biologic medication that has transformed the treatment landscape for various types of arthritis, including rheumatoid arthritis and psoriatic arthritis. As a TNF inhibitor, it targets specific inflammatory pathways, leading to substantial reductions in disease activity and improvements in patient quality of life. The increased adoption of adalimumab, driven by its effectiveness and favorable dosing regimen, is anticipated to boost the biologics segment. Furthermore, the introduction of biosimilars is expected to increase competition within this class, potentially making treatments more accessible to a broader patient population. As awareness of the benefits of biologic therapies grows, adalimumab will likely remain a key player in the arthritis medications market.

By Region

The North American region holds the largest share of the prescription arthritis medications market, with a valuation exceeding USD 35 billion in 2023. This dominance can be attributed to the high prevalence of arthritis conditions, significant healthcare expenditure, and a well-established pharmaceutical infrastructure. The region's aging population and increased participation in healthcare services further bolster demand for arthritis medications. Additionally, ongoing research and development initiatives, coupled with the presence of leading pharmaceutical companies, contribute to North America's robust market growth. The CAGR for the North American market is projected to be around 6.5%, driven by innovations in product development and increasing awareness among healthcare professionals and patients alike.

Europe is another major market for prescription arthritis medications, expected to reach approximately USD 30 billion by 2035. The region's growing elderly population, coupled with rising healthcare costs, is driving up demand for effective arthritis treatments. Various countries within Europe are also focusing on improving healthcare accessibility and affordability, encouraging wider usage of available medications. Furthermore, the increasing adoption of biologic therapies and innovative treatment options is expected to fuel market growth. Emerging economies in Eastern Europe are also witnessing a rise in arthritis prevalence, which will contribute to the overall market expansion. As a result, the European market is poised for a CAGR of approximately 7.0% over the forecast period.

Opportunities

The prescription arthritis medications market presents numerous opportunities for growth, particularly in the realm of novel therapies and personalized medicine. As research and development efforts continue to advance, pharmaceutical companies are likely to introduce innovative treatment options that specifically target the underlying causes of arthritis rather than merely alleviating symptoms. The development of biosimilars and generics will create additional opportunities to enhance market access and affordability for patients. Furthermore, the increasing emphasis on preventive healthcare and early intervention will lead to heightened demand for arthritis medications, creating a conducive environment for market players to expand their product portfolios. Additionally, collaboration between pharmaceutical companies and healthcare providers to improve patient education and adherence to prescribed treatment regimens will also create significant opportunities for growth.

Moreover, the integration of digital health technologies and telemedicine services offers further opportunities for the arthritis medications market. With the rising incidence of chronic diseases and the growing demand for remote healthcare, digital health platforms enable patients to access healthcare services conveniently. Telemedicine not only enhances patient engagement but also facilitates regular monitoring and follow-up, which can lead to better management of arthritis conditions. Companies that leverage digital health solutions alongside their offerings will likely gain a competitive advantage in the market. Overall, the evolving landscape of healthcare, characterized by technological advancements and patient-centric approaches, provides substantial growth opportunities in the prescription arthritis medications market.

Threats

Despite the optimistic growth outlook for the prescription arthritis medications market, several threats could hinder progress. One of the most significant threats is the increasing prevalence of counterfeit and substandard drugs in the pharmaceutical market. These fake medications pose serious risks to patient health and undermine the credibility of legitimate pharmaceutical companies. Regulatory bodies are striving to combat this issue through stringent monitoring; however, the presence of counterfeit medicines remains a concern. Additionally, the rising trend of self-medication and over-the-counter alternatives may lead to reduced prescription rates, impacting the market for prescription medications. The growing use of alternative therapies and natural remedies may also pose a challenge, as they could divert patients from conventional medication.

Furthermore, the high cost associated with certain advanced therapies, particularly biologics, can limit patient access and adherence. Patients facing high out-of-pocket expenses may opt for less effective treatment options, leading to poor disease management and reduced market growth. The potential for regulatory changes and shifts in healthcare policies could also affect market dynamics, particularly in regions where cost containment measures are being implemented. Lastly, the global economic uncertainties and challenges posed by the COVID-19 pandemic have led to fluctuations in healthcare spending, which may affect the overall growth of the prescription arthritis medications market.

Competitor Outlook

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis AG
• Sandoz International GmbH
• Pfizer Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• UCB S.A.
• Horizon Therapeutics plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.

The competitive landscape of the prescription arthritis medications market is characterized by a mix of well-established pharmaceutical giants and emerging players focused on innovative therapies. AbbVie Inc. is a market leader, primarily due to its flagship drug, Humira (adalimumab), which has significantly impacted the treatment of various arthritis forms. The company continues to invest heavily in research and development to maintain its competitive edge and explore new indications for its existing products. Similarly, Amgen Inc. and Johnson & Johnson are also prominent players in the market, known for their comprehensive portfolios that encompass both traditional and biologic therapies. Their focus on patient-centric approaches and personalized medicine further enhances their market positions.

Moreover, Novartis AG and Pfizer Inc. are actively expanding their offerings through strategic partnerships and collaborations to develop novel therapies. Novartis has prioritized the development of innovative biologics for autoimmune diseases, while Pfizer continues to leverage its extensive research capabilities to enhance patient outcomes. The presence of Sandoz, a division of Novartis, adds another layer of competition in the generic and biosimilar segments, driving down prices and increasing market access for patients. Furthermore, emerging companies like Horizon Therapeutics and UCB S.A. are gaining traction by focusing on niche markets and developing specialized therapies targeting specific arthritis conditions.

In conclusion, the prescription arthritis medications market is poised for significant growth as companies continue to innovate and develop new therapies. The competitive landscape is evolving, with established players and newcomers alike striving to meet the increasing demand for effective arthritis treatments. With the emphasis on personalized medicine and the integration of digital health technologies, companies that adapt swiftly to market changes will be well-positioned for success. As stakeholders continue to prioritize patient outcomes and invest in research and development, the future of the arthritis medications market looks promising.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 UCB S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Horizon Therapeutics plc
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sandoz International GmbH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bristol-Myers Squibb Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Prescription Arthritis Medications Market, By Application
    • 6.1.1 Osteoarthritis
    • 6.1.2 Rheumatoid Arthritis
    • 6.1.3 Psoriatic Arthritis
    • 6.1.4 Ankylosing Spondylitis
    • 6.1.5 Others
  • 6.2 Prescription Arthritis Medications Market, By Ingredient Type
    • 6.2.1 Celecoxib
    • 6.2.2 Ibuprofen
    • 6.2.3 Methotrexate
    • 6.2.4 Prednisone
    • 6.2.5 Adalimumab
  • 6.3 Prescription Arthritis Medications Market, By Distribution Channel
    • 6.3.1 Hospital Pharmacies
    • 6.3.2 Retail Pharmacies
    • 6.3.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Prescription Arthritis Medications Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Prescription Arthritis Medications market is categorized based on

By Application

• Osteoarthritis
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Celecoxib
• Ibuprofen
• Methotrexate
• Prednisone
• Adalimumab

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis AG
• Sandoz International GmbH
• Pfizer Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• UCB S.A.
• Horizon Therapeutics plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.